A bacterial defense system called SPARDA employs kamikaze-like tactics to protect cells and could be useful in future ...

PulseSight Therapeutics SAS, an ophthalmology clinical stage biotech company developing disruptive vectorized gene therapies with minimally-invasive delivery technology, is pleased to announce the ...

Explore RNA interference methods, comparing siRNA and shRNA for gene knockdown, their mechanisms, advantages, and ...

PulseSight Therapeutics completes patient enrolment in phase I trial of PST-611 to treat dry AMD/geographic atrophy: Paris, France Friday, January 23, 2026, 18:00 Hrs [IST] PulseS ...

Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing ...

IntraBio Inc. today announced positive topline results from its pivotal Phase III IB1001-303 clinical trial, "Effects of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T): A Randomized, ...

Validated next-generation sequencing soon will become necessary in ensuring the safety and efficacy of cell and gene ...